GlassScriptPhysician profile
Kevin Michael Douglass
NPI 1487003943
$3,283.29
in general payments reported to CMS, 2019-2025
27 companies · $832 in 2025
The $832 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.13 · 2021: $199 · 2022: $262 · 2023: $1,010 · 2024: $964 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717 · Education: $88.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.94 |
| Education | $88.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.56 | 2020-2025 | Skyrizi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $647.24 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $267.31 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $218.48 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $185.70 | 2023-2025 | |
| Daiichi Sankyo INC. | $76.36 | 2023 | Injectafer |
| Madrigal Pharmaceuticals | $73.75 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $72.78 | 2024-2025 | Terlivaz |
| Celltrion USA INC. | $72.77 | 2023-2024 | Zymfentra, Yuflyma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.13 | 2022-2024 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $63.61 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $55.24 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $50.54 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $43.16 | 2023-2024 | Dificid |
| Organon LLC | $41.33 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38.97 | 2022-2023 | Avsola, Amjevita |
| Ferring Pharmaceuticals INC. | $35.91 | 2023-2024 | Rebyota |
| Qol Medical, LLC | $33.49 | 2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $32.41 | 2023-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $21.00 | 2025 | Iqirvo |
| Mylan Institutional INC. | $18.46 | 2023 | Hulio |
| Sandoz INC. | $18.25 | 2024 | Hyrimoz |
| Ardelyx, INC. | $16.44 | 2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Celgene Corporation | $15.45 | 2024 | Zeposia |
| Boston Scientific Corporation | $13.57 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.27 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Douglass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.